Autosomal dominant polycystic kidney disease
Conditions
Interventions
FMD:fasting-mimicking diet
Control:none
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Patients with confirmed diagnosis of ADPKD in combination with family history, imaging and/or genetic testing; 2. Aged 18-50 years, gender not limited; 3. eGFR >= 60 ml/min and consistent with rapidly progressive ADPKD, meeting one of the following indicators; (1) MRI measurement of total kidney volume TKV >= 750 ml; (2 PROPKD score of high risk (> 6); 4. Body mass index (BMI) between 19.0-24.0 kg/m2 and occupation of light manual labor; 5. Subjects signed informed consent; 6. Subjects have access to the internet and participate in webcam communication.
Exclusion criteria
Exclusion criteria: 1. Use of medications such as tolvaptan and metformin in the last 1 month; 2. Metabolic disorders such as type 1 or type 2 diabetes, uncontrolled hyperthyroidism, impaired fatty acid metabolism (e.g. carnitine deficiency); 3. Significant organ disease, including: history of pancreatitis, active gallbladder disease, moderate to severe liver impairment, frequent gout, severe heart/lung disease, malignancy, etc. Severe gastrointestinal disease (including: chronic malabsorption, peptic ulcer disease, Crohn's disease, ulcerative colitis, chronic diarrhea, or active gallbladder disease), severe pulmonary disease (including: chronic obstructive pulmonary disease, interstitial lung disease, cystic fibrosis, or uncontrolled asthma); 4. Malnutrition, Alb < 35 g/L; 5. Alcohol abuse, special diets (vegetarianism), regular use of prescription or over-the-counter medications that may affect weight, appetite, food intake, or energy metabolism (e.g., appetite suppressants, lithium, stimulants, antipsychotics, tricyclic antidepressants); regular use of obesity medication within the past 6 months; 6. Patients who cannot tolerate MRI examinations (claustrophobia, metal implants in the body, etc.); 7. Patients who are unable to care for themselves; 8. Patients who cannot follow up on time; 9. Pregnant/lactating women, or those with pregnancy plans; 10. Participating in other clinical trials; 11. not considered suitable by the investigator to participate in clinical studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility;safety and tolerability; | — |
Secondary
| Measure | Time frame |
|---|---|
| eGFR;24 h UTP;total kidney volume;Quality of life score;PCR; | — |
Countries
China
Contacts
Public ContactXujie Zhou
Peking University First Hospital
Outcome results
None listed